
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
about 19 years ago
Review Questionsabout 19 years ago
Improving Pharmaceutical Care of the Elderly Patient With GERD





